Aura Biosciences Lays Off 20% of Workforce, Overhauls C-Suite in R&D Pivot
NewsData.io · United States · Aug 11, 2026
Boston biotech Aura Biosciences is cutting approximately 20% of its workforce — roughly 22 positions based on its 113 full-time employees as of February — as new CEO Natalie Holles refocuses the company exclusively on ocular oncology. The restructuring carries a severance cost of $2.9M–$3.2M and includes a full C-suite overhaul, with three new executives installed and three departing. The company extended its cash runway to early 2029 as a result of the strategic pullback from bladder cancer research.
Get the weekly brief by email
What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.
Related stories
Detroit ABC affiliate WXYZ-TV (Channel 7) has eliminated at least 30 positions through a combination of buyouts and layoffs, according to sources who…
Dole Packaged Foods will permanently close its Atwater, California processing facility and a nearby Livingston laboratory, eliminating 404 jobs in…
About 1,400 IRS IT employees displaced by DOGE-directed downsizing have been reorganized into 'ONE IRS Readiness' teams with no defined mission…
Lufthansa plans to eliminate 1,000 full-time positions at its flagship carrier, with reductions targeted at its Frankfurt and Munich hubs…